Washington -Fedient officials approved a new type of painkillers on Thursday, which aims to eliminate and Opioid Pharmaceuticals and other drugs such as Vicotine and hydroxycin.
The US Food and Drug Administration stated that it approved the drug Journavx of Vertex Pharmaceuticals for short -term pain after surgery or injury.
This is the first new drug that treats pain in more than 20 years. It provides alternatives for opioid drugs and non -prescription drugs, such as ibuprofen and acetamol. However, the moderate effectiveness and long development process of the drug emphasize the challenge to find new methods to control pain.
Vertex Pharmaceuticals via AP
Two studies from 870 patients with acute pain were performed after foot and abdominal surgery that the drugs of the peptic provided more relief than virtual drugs, but it did not show ordinary opiocene acetaminophenol.
Mayo Schuh, a pharmacist and pain medical expert who did not participate in the study, said: “This is not a slam dunk for effectiveness.” “But this is a slam dunk because this is a very different way And the engine, so I think this shows a lot of hope. ”
Vertex began to study the drug in the 1920s. At that time, excessive drugs rose, mainly by large -scale prescriptions of opioid analgesic drugs, such as common diseases such as arthritis and back pain. The prescription has dropped sharply in the past ten years, and the current opioids are mainly due Illegal fentiniNot a drug.
Oed drugs reduce pain by binding to the brain receptor that receives nerve signals from different parts of the body. These chemical interactions can also cause an addictive effect of opioids.
The role of the drug's drug is different, which prevents the protein that triggers the pain signal, and these proteins are later sent to the brain.
Dr. Vertex's David Altshuler told the Associated Press last year: “When trying to develop drugs with addictive risks without opioids, a key factor is to work hard to prevent pain before the pain signal spread.”
The side effects of this drug are nausea, constipation, itching, rash and headache.
Dr. Charles Argoff of the Olbani Medical Center said: “New drugs have side effects, not only inherently different, but also do not involve other key side effects of the risk of abuse of drugs and other key side effects related to opioid drugs.” develop.
The initial concept of focusing on pain signal protein was not sensitive to pain from those involving rare genetic diseases.
Vertex has attracted interest in Wall Street because its ambitious pharmaceutical pipelines involve the winning FDA approval to win a variety of drugs in several forms of chronic pain, which usually represents greater financial opportunities than acute pain.
However, the stock price of this Boston pharmaceutical dealer plummeted in December. At that time, the disappointment of the apex caused the research on the back and legs of chronic nerve pain. The study found that the performance of the drug was not significantly higher than the placebo.
Biotechnology analyst, Brian Abrahams, said in a description of investors: “We believe that data reflects almost the worst case of this key channel plan.” He added that the result ended the end Vertex's pipelines may be worth more than billions of forms of pain.
Vertex executives said they planned to conduct new post -research on the drug, so that the theory believes that different test design can produce better results and pave the way for FDA to approve chronic pain.
